Oncolytics Biotech Inc(ONCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ONCY Oncolytics Biotech Inc

Trading 04-23 10:26:08 EDT

1.14

-0.01

-0.86%

High1.15	Low1.11	Vol56.42K
Open1.11	D1 Closing1.15	Amplitude3.48%
Mkt Cap132.40M	Tradable Cap129.97M	Total Shares116.13M
T/O64.06K	T/O Rate0.05%	Tradable Shares114.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ONCY","market":"US","secType":"STK","nameCN":"Oncolytics Biotech Inc","latestPrice":1.1401,"timestamp":1776954334841,"preClose":1.15,"halted":0,"volume":56415,"delay":0,"changeRate":-0.00860869565217393,"floatShares":113999999,"shares":116128162,"eps":-0.300019,"marketStatus":"Trading","change":-0.0099,"latestTime":"04-23 10:26:08 EDT","open":1.11,"high":1.15,"low":1.11,"amount":64060.462347,"amplitude":0.034783,"askPrice":1.15,"askSize":3884,"bidPrice":1.14,"bidSize":3748,"shortable":3,"etf":0,"ttmEps":-0.300019,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1776974400000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1002254400000,"exchange":"NASDAQ","adjPreClose":1.15,"preHourTrading":{"tag":"盘前","latestPrice":1.13,"preClose":1.15,"latestTime":"09:14 EDT","volume":3527,"amount":4043.2727370999996,"timestamp":1776950048411,"change":-0.02,"changeRate":-0.017391,"amplitude":0.032},"postHourTrading":{"tag":"盘后","latestPrice":1.1574,"preClose":1.15,"latestTime":"19:19 EDT","volume":408,"amount":472.41,"timestamp":1776899949293,"change":0.0074,"changeRate":0.006435,"amplitude":0.006435},"volumeRatio":0.483227},"requestUrl":"/m/hq/s/ONCY","defaultTab":"news","newsList":[{"id":"2628824927","title":"Top News Today: Stocks Rise Amid Hopes for Further U.S.-Iran Talks","url":"https://stock-news.laohu8.com/highlight/detail?id=2628824927","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628824927?lang=en_us&edition=fundamental","pubTime":"2026-04-17 04:31","pubTimestamp":1776371460,"startTime":"0","endTime":"0","summary":"TREASURYS: Treasury yields rose as another up-tick in oil prices stoked inflation concerns.COMMODITIES: Oil futures settled higher after U.S. officials indicated a tightening of the blockade of ships in and out of Iranian ports.Netflix Chair Reed Hastings to Leave Board in June. Netflix Chairman and co-founder Reed Hastings will step down from the company's board after his term expires in June, the streaming giant said Thursday.Cutting Prices on Doritos Has Paid Off, PepsiCo Says. In February, PepsiCo said it would cut prices on some of its chips and snacks by as much as 15%, in a bid to woo cost-conscious consumers back to snacks like Lay's potato chips and Doritos. The company found affordability was a big reason why consumers held back from purchases. In some markets, the price of some large bags of chips cost well over $6.Abbott Laboratories Cuts Outlook, Says Mild Flu Season Hurt Sales. Abbott attributed the lower outlook to its acquisition of cancer-diagnostics company Exact Scie","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"a82f876c315cf798ee69d53113741722","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMI","NROM","ONCY","FITB","LU2237957902.USD","LU0077335932.USD","LU0097036916.USD","BK4548","LU0106831901.USD","BK4561","LU0882574139.USD","LU1989764664.SGD","LU1429558221.USD","NFLW","NFLP","CARM","LU1035775433.USD","NFLX","BK4585","LU1668664300.SGD","LU1814569148.SGD","SGXZ23171101.USD","NECB","NFLY","LU1366192091.USD","NFXS","BK4207","CCNE","CWBC","NFLU","PKBK","LU0106261372.USD","RF","LU0256863811.USD","MPU","LU0234570918.USD","LU1880398554.USD","LU0082616367.USD","LU1064131342.USD","LU0417517546.SGD","LU0868494708.USD","LU2461242641.AUD","LU1548497426.USD","ALLY","IE00BKPKM429.USD","AAME","LU1791807156.HKD","NFXL","SGXZ51526630.SGD","LU1674673428.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625602278","title":"Analysts Conflicted on These Healthcare Names: Oncolytics Biotech (ONCY) and Neurocrine (NBIX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2625602278","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625602278?lang=en_us&edition=fundamental","pubTime":"2026-04-07 05:50","pubTimestamp":1775512205,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Oncolytics Biotech (ONCY) and Neurocrine (NBIX). O...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-oncolytics-biotech-oncy-and-neurocrine-nbix-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-oncolytics-biotech-oncy-and-neurocrine-nbix-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","XBI","LU0029874061.USD","LU0320765992.SGD","LU2065170008.USD","LU0154245673.USD","BK4581","LABU","LU0889565916.HKD","LU0128526141.USD","LU0154245756.USD","LU0823416689.USD","XLV","HCSG","LU2065171402.SGD","NBIX","BK4137","LU2065169927.USD","LU2324357040.USD","BK4588","ONCY","BK4139","LU2065171311.SGD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625097506","title":"Oncolytics Biotech signs Jefferies ATM equity sale agreement for up to $75 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2625097506","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625097506?lang=en_us&edition=fundamental","pubTime":"2026-04-07 04:13","pubTimestamp":1775506414,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech entered an at-the-market equity distribution agreement with Jefferies for up to USD 75 million of common stock.Jefferies will sell shares from time to time based on company instructions.Sales will be made off a Form S-3 shelf registration statement declared effective April 3, 2026.Agent commission set at up to 3% of gross proceeds.Net proceeds earmarked for pelareorep clinical development, related R&D, operating costs, working capital.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 06, 2026, a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nNDLc9Nmqh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ONCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625751609","title":"Oncolytics Biotech Inc - to Offer and Sell Common Stock up to $75 Mln Through Jefferies - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2625751609","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625751609?lang=en_us&edition=fundamental","pubTime":"2026-04-07 04:13","pubTimestamp":1775506388,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nFWN40N025:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ONCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625142603","title":"BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Norfolk Southern, Denali","url":"https://stock-news.laohu8.com/highlight/detail?id=2625142603","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625142603?lang=en_us&edition=fundamental","pubTime":"2026-04-07 01:51","pubTimestamp":1775497861,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Norfolk Southern, DenaliWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nL6N40P09M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATMU","BKNG","RKT","IDYA","TSLT","XOM","OXY","ADM","KTOS","WLK","AVGO","NVDD","FAF","ELAB","TSN","EXPE","TSLI","LYB","TSLA","DVN","NSC","DOW","CVNY","NVDA","07766","PRAX","CVNX","TSLR","CVX","DIPS","AESI","VLO","TSLZ","PFSA","ONCY","TSLY","QCOM","NVD","TSLW","IBRX","SLNO","LGN","WTBA","CAR","CVNA","AGPU","TLA","DNLI","TSLS","AMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625670663","title":"BUZZ-U.S. STOCKS ON THE MOVE-Tyson Foods, Atmus Filtration, Avis Budget","url":"https://stock-news.laohu8.com/highlight/detail?id=2625670663","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625670663?lang=en_us&edition=fundamental","pubTime":"2026-04-06 23:44","pubTimestamp":1775490252,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Tyson Foods, Atmus Filtration, Avis BudgetWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nL6N40P0IG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRAX","WTBA","LYB","AVGU","AVGO","DOW","CVX","NVDA","CVNA","QCMD","SNVD.UK","ATMU","OXY","BKNG","FAF","ELAB","AMYY","XOM","AGPU","AMUU","VLO","AMDL","TSN","ONCY","PFSA","ADM","AMDU","AMDD","DVN","AVGG","QCMU","DIPS","CAR","LGN","QCML","SLNO","AMDW","KTOS","ANV","QCOM","EXPE","AMD","AMDY","AESI","KTUP","RKT","AMDG","WLK","IBRX","IDYA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625672933","title":"BUZZ-Oncolytics rises as it schedules FDA talks on anal cancer drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2625672933","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625672933?lang=en_us&edition=fundamental","pubTime":"2026-04-06 22:02","pubTimestamp":1775484177,"startTime":"0","endTime":"0","summary":"BUZZ-Oncolytics rises as it schedules FDA talks on anal cancer drug** Shares of biotech firm Oncolytics Biotech ONCY.O rise 2% to $0.97** Co says it will meet the FDA on April 16 to discuss a possible approval path for its experimental anal cancer drug pelareorep** This rare cancer starts in anal canal and few options exist once standard treatments fail** Co says it plans to propose a singlearm study combining pelareorep with a type of cancer immunotherapy in patients who have no approved alternatives** Earlier study showed about a 30% tumor response rate lasting around 17 months, compared with 10%–14% and about 9.5 months for existing options, co says** Including session's move, stock up ~12% YTD","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nL4N40P0PL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ONCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625603672","title":"Oncolytics schedules FDA meeting for pelareorep registrational path","url":"https://stock-news.laohu8.com/highlight/detail?id=2625603672","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625603672?lang=en_us&edition=fundamental","pubTime":"2026-04-06 21:56","pubTimestamp":1775483771,"startTime":"0","endTime":"0","summary":"Oncolytics (ONCY) announced it has scheduled a Type C meeting with the FDA on April 16, to discuss a potential registrational development path for ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oncolytics-schedules-fda-meeting-for-pelareorep-registrational-path-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oncolytics-schedules-fda-meeting-for-pelareorep-registrational-path-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ONCY","LABU","BK4585","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625088671","title":"Oncolytics schedules FDA Type C meeting on single-arm registrational pathway for pelareorep in anal cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2625088671","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625088671?lang=en_us&edition=fundamental","pubTime":"2026-04-06 21:00","pubTimestamp":1775480443,"startTime":"0","endTime":"0","summary":"Oncolytics scheduled Type C meeting with FDA for April 16, 2026 to discuss registrational path for pelareorep in squamous cell anal carcinoma.Discussion set to cover potential single-arm pivotal study of pelareorep plus checkpoint inhibitor in second-line or later patients, targeting about 60-70 enrollment.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nNDL8BYSS5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","NDAQ","IE00BN0W2W23.USD","LU2095319765.USD","IE00B64PRP62.GBP","SG9999014021.USD","LU2210150020.SGD","IE00BKPKM429.USD","BK4585","IE00BN0W2T93.GBP","IE00BGHQF748.EUR","SG9999014013.SGD","BK4588","IE00BN0W2V16.EUR","BK4112","BK4139","LU0314104364.USD","IE00B3QW5Z07.USD","ONCY","SG9999014005.SGD","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625767174","title":"Oncolytics Biotech Inc - Schedules Type C FDA Meeting on April 16, 2026 for Pelareorep in Anal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2625767174","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625767174?lang=en_us&edition=fundamental","pubTime":"2026-04-06 21:00","pubTimestamp":1775480402,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nTUABQPCYK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ONCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625671080","title":"Oncolytics Biotech Inc - Meeting to Discuss Single-Arm Pivotal Study of Pelareorep in Second-Line and Later Scac","url":"https://stock-news.laohu8.com/highlight/detail?id=2625671080","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625671080?lang=en_us&edition=fundamental","pubTime":"2026-04-06 21:00","pubTimestamp":1775480402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nTUABQPCYK:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ONCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624682125","title":"Top News Today/Canada: Goods-Trade Deficit Widens, Surplus With U.S. Narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2624682125","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624682125?lang=en_us&edition=fundamental","pubTime":"2026-04-03 04:29","pubTimestamp":1775161740,"startTime":"0","endTime":"0","summary":"Goods-Trade Deficit Widens to Six-Month High Even as Trade With Non-U.S. Nations Increases. Canada's trade deficit with the world surged to a six-month high as shipments of gold drove imports to record levels, though evidence is growing the country's dependence on the massive U.S. market is easing.The country recorded a merchandise-trade deficit in February of C$5.74 billion, Statistics Canada said Thursday. That was much larger than the C$2.5 billion shortfall economists anticipated.Imports jumped 8.4% between January and February to an all-time high of C$72.05 billion as inbound shipments of gold led widespread increases, outpacing a 6.4% rise in exports to C$66.31 billion, the highest since March of last year when the first wave of the Trump administration's tariffs kicked in.Telecom Stocks Drop as TD Cowen Downgrades Sector on Price War Pressures. Canadian telecom stocks slipped after TD Cowen cut its outlook on the sector amid mounting pressure from aggressive mobile-plan pricing.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4096","BK4117","SMXT","BK4147","ATLN","BK4007","CARM","BK4104","AAME","RBCN","BPTH","ONCY","SCLX","BK4185","NROM","BK4600","BK4209","MPU","QNCX","RHEP","BK4524","BK4108","SONM","BK4507","BK4139","BK4170","NWBO","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624344511","title":"Oncolytics completes domicile change to the U.S.","url":"https://stock-news.laohu8.com/highlight/detail?id=2624344511","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624344511?lang=en_us&edition=fundamental","pubTime":"2026-04-01 21:39","pubTimestamp":1775050777,"startTime":"0","endTime":"0","summary":"Oncolytics (ONCY) announced the completion of the previously announced change in the jurisdiction of incorporation of Oncolytics from the Province ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oncolytics-completes-domicile-change-to-the-u-s-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oncolytics-completes-domicile-change-to-the-u-s-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ONCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624951644","title":"Oncolytics Biotech shifts headquarters to San Diego, completes Nevada domestication","url":"https://stock-news.laohu8.com/highlight/detail?id=2624951644","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624951644?lang=en_us&edition=fundamental","pubTime":"2026-04-01 21:02","pubTimestamp":1775048541,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech completed a corporate domicile change to United States, shifting incorporation from Alberta to Nevada.San Diego office becomes new headquarters, while Calgary office is retained.Domestication took effect March 31, 2026 following filings with Nevada Secretary of State.Company cited operational efficiency, streamlined regulatory structure, improved access to U.S. capital markets.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL3nLpHg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4112","IE00B64PRP62.GBP","IE00BN0W2V16.EUR","SG9999014013.SGD","LU2210149790.SGD","NDAQ","LU2210150020.SGD","IE00BKPKM429.USD","BK4588","SG9999014021.USD","ONCY","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","BK4139","LU0314104364.USD","SG9999014005.SGD","LU2095319765.USD","SG9999014039.USD","IE00BN0W2W23.USD","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624940995","title":"Oncolytics files $250M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2624940995","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624940995?lang=en_us&edition=fundamental","pubTime":"2026-04-01 18:11","pubTimestamp":1775038298,"startTime":"0","endTime":"0","summary":"06:07 EDT Oncolytics (ONCY) files $250M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving breakin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oncolytics-files-250m-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oncolytics-files-250m-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ONCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624594511","title":"Oncolytics Biotech Inc - May Offer up to $250 Mln in Aggregate Securities - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2624594511","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624594511?lang=en_us&edition=fundamental","pubTime":"2026-04-01 18:06","pubTimestamp":1775038013,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nFWN40J204:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ONCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623732843","title":"Oncolytics Biotech Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2623732843","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623732843?lang=en_us&edition=fundamental","pubTime":"2026-03-31 09:01","pubTimestamp":1774918918,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech Inc reports results for the quarter ended December 31 - Earnings SummaryOncolytics Biotech Inc ONCY.OQ reported a quarterly adjusted loss of 8 cents per share for the quarter ended ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nL8N40J017:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623532455","title":"Oncolytics FY25 net loss widens to $ US 29M; operating loss grows to $ US 29M","url":"https://stock-news.laohu8.com/highlight/detail?id=2623532455","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623532455?lang=en_us&edition=fundamental","pubTime":"2026-03-31 05:32","pubTimestamp":1774906358,"startTime":"0","endTime":"0","summary":"Oncolytics posted net loss of USD 29 million, widening from USD 23 million.Operating loss expanded to USD 29 million from USD 26 million as operating expenses climbed to USD 29 million from USD 26 million.Research and development expense fell to USD 13 million from USD 15 million, while general and administrative costs rose to USD 15 million from USD 10 million on higher public company-related expenses tied to domestication activities and TSX delisting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 30, 2026, an","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL8bG9sw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ONCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622273852","title":"Geron appoints Patricia S. Andrews and Constantine Chinoporos to board of directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2622273852","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622273852?lang=en_us&edition=fundamental","pubTime":"2026-03-26 20:04","pubTimestamp":1774526679,"startTime":"0","endTime":"0","summary":"Patricia Andrews is a board member at Glenmark Pharmaceuticals and Oncolytics Biotech, and previously served as CEO of Sumitomo Pharma Oncology from 2017 to 2023.Constantine Chinoporos previously served as COO and chief business officer at Applied Therapeutics from 2023 until its acquisition by Cycle Pharmaceuticals in 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL913xVY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","LU2095319765.USD","BK4112","SG9999014039.USD","BK4588","IE00B64PRP62.GBP","BK4139","SG9999014021.USD","SG9999014013.SGD","LU0314104364.USD","LU2210150020.SGD","SG9999014005.SGD","IE00B3QW5Z07.USD","NDAQ","ONCY","BK4585","IE00BGHQF748.EUR","IE00BN0W2V16.EUR","GERN","IE00BN0W2W23.USD","LU2210149790.SGD","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620273897","title":"Oncolytics Biotech Showcases Pelareorep as Immune-Priming Backbone With New AACR 2026 Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2620273897","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620273897?lang=en_us&edition=fundamental","pubTime":"2026-03-20 02:05","pubTimestamp":1773943540,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech ( ($ONCY) ) just unveiled an announcement. Oncolytics Biotech will present new mechanistic and translational data at the AACR 20...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/oncolytics-biotech-showcases-pelareorep-as-immune-priming-backbone-with-new-aacr-2026-data?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/oncolytics-biotech-showcases-pelareorep-as-immune-priming-backbone-with-new-aacr-2026-data?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4595","ONCY","BTFL","BK4585","BK4600","BK4023","BK4588","BK4581"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.oncolyticsbiotech.com","stockEarnings":[{"period":"1week","weight":0.0455},{"period":"1month","weight":0.214},{"period":"3month","weight":-0.0945},{"period":"6month","weight":-0.0417},{"period":"1year","weight":0.9224},{"period":"ytd","weight":0.3158}],"compareEarnings":[{"period":"1week","weight":0.0161},{"period":"1month","weight":0.0852},{"period":"3month","weight":0.0323},{"period":"6month","weight":0.0501},{"period":"1year","weight":0.3489},{"period":"ytd","weight":0.043}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.001975},{"month":2,"riseRate":0.25,"avgChangeRate":-0.025046},{"month":3,"riseRate":0.125,"avgChangeRate":-0.123611},{"month":4,"riseRate":0.75,"avgChangeRate":0.064366},{"month":5,"riseRate":0.285714,"avgChangeRate":-0.009291},{"month":6,"riseRate":0.285714,"avgChangeRate":0.190573},{"month":7,"riseRate":0.5,"avgChangeRate":0.009647},{"month":8,"riseRate":0.25,"avgChangeRate":-0.092405},{"month":9,"riseRate":0.125,"avgChangeRate":-0.025103},{"month":10,"riseRate":0.5,"avgChangeRate":0.144514},{"month":11,"riseRate":0.25,"avgChangeRate":0.020161},{"month":12,"riseRate":0.125,"avgChangeRate":0.270533}],"exchange":"NASDAQ","name":"Oncolytics Biotech Inc","nameEN":"Oncolytics Biotech Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Oncolytics Biotech Inc(ONCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Oncolytics Biotech Inc(ONCY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Oncolytics Biotech Inc,ONCY,Oncolytics Biotech Inc股票,Oncolytics Biotech Inc股票老虎,Oncolytics Biotech Inc股票老虎国际,Oncolytics Biotech Inc行情,Oncolytics Biotech Inc股票行情,Oncolytics Biotech Inc股价,Oncolytics Biotech Inc股市,Oncolytics Biotech Inc股票价格,Oncolytics Biotech Inc股票交易,Oncolytics Biotech Inc股票购买,Oncolytics Biotech Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Oncolytics Biotech Inc(ONCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Oncolytics Biotech Inc(ONCY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction